Newsletter · · Ashutosh Agarwal

FDA Clears uniQure to File Its Huntington's Gene Therapy Without a Sham-Surgery Control - Biotech Pipeline: Gene/Cell, Neuro & Tools - Week of June 21, 2026

Gene, cell, neuro and tools newsletter for the week of June 21, 2026. The FDA cleared uniQure to file its Huntington's gene therapy without the sham-surgery control the prior regime demanded, while in-vivo gene/cell therapy became the field's center of gravity and delivery, not the editor, emerged as the real bottleneck.

Biotech Pipeline: Gene/Cell, Neuro & Tools

Week of June 21, 2026: FDA Clears uniQure to File Its Huntington's Gene Therapy Without a Sham-Surgery Control

A year of trench warfare with the FDA ended this week not with a court fight but with a handshake. The agency agreed to accept a filing for a Huntington's gene therapy it had spent the spring publicly trashing, and quietly dropped the one requirement, a sham brain surgery, that the patient community had called a death sentence. Read it narrowly and it's one rare-disease drug clearing one regulatory gate. Read it the way a gene-therapy investor should and it's a tell: with the prior leadership gone, the FDA is once again a place where in-vivo and CNS programs can get a fair hearing. The rest of the week's tape, viral-vector engineering, large-gene delivery, cell-therapy manufacturing, only matters because the gate is open again.

TL;DR

  • The FDA cleared uniQure (QURE) to file its Huntington's gene therapy, submission slated for Q3, on accelerated approval with a confirmatory trial, and crucially without the sham-surgery control the prior regime demanded. The pivotal data slowed progression ~75% at three years. (The Readout Loud, Jun 18)
  • In-vivo is now the center of gravity in gene/cell therapy, Eli Lilly's ORNA buy (in-vivo CAR-T on circular RNA), Intellia's in-vivo CRISPR and Regeneron's in-vivo program were all flagged as the defining moves of 2026, with the field racing to deliver "beyond the liver." (Cell & Gene, Jun 18)
  • Delivery, not the editor, is the bottleneck, and the money agrees. Capsid engineering plus AI to retarget AAV, and a split-intein trick to fit large genes into AAV, were the two cleanest delivery stories of the week. (Discovery Matters, Jun 18; RARECast, Jun 18)

What's new

The FDA blinked on Huntington's, and the way it blinked is the signal. On the June 18 Readout Loud, STAT's Adam Feuerstein and Allison DeAngelis walked through uniQure's reversal: after the agency under Marty Makary and Vinay Prasad called the data insufficient, and after an anonymous senior official told reporters in March the company was pushing "distorted and manipulated" data for a "failed therapy," the two sides "hammered out an agreement that clears a path" for a Q3 filing under accelerated approval with a confirmatory trial. The underlying data "slowed the progression of Huntington's by 75% after three years," against current drugs that only treat symptoms. The kicker for anyone modeling gene-therapy timelines: the FDA appears to have dropped the sham-surgery control the prior leadership insisted on. Patient advocate Lauren Holder, who has early-stage HD, called that old requirement "a death sentence to our community" and tied the turn directly to the leadership change, "I do think it has a lot to do with it." (The Readout Loud)

In-vivo went from thesis to league table. On the June 18 Better Biopharma editors' roundtable, the panel's read on 2026 so far was that "in vivo approaches and smarter delivery platforms... are getting a lot more attention," with three names doing the defining: Intellia's in-vivo CRISPR therapy, Regeneron's in-vivo program (called "a defining moment for in vivo gene therapy"), and Eli Lilly's acquisition of ORNA, "another in vivo CAR-T company working with circular RNA," one of "a couple of acquisitions that broke the bank." The editors were candid that the field's hardest problem has moved: "how much more effort is going into getting beyond the liver," into "lungs, lymph nodes, kidneys, pancreas, CNS." And they noted the skeptics out loud, "not everybody is on board with thinking that in vivo is going to be the answer." (Cell & Gene)

The whole field is converging on the same chokepoint: getting the package to the right address. On Discovery Matters (a Cytiva production), Westlake University's Dr. Lijia Ma laid out why vectors "really like to go to the liver" and why steering them elsewhere, past the blood-brain barrier, into muscle and heart, is the breakthrough of the moment, achieved by "changing a couple of amino acids in the surface of the virus," now increasingly guided by AI trained across an enormous design "search space." Cytiva's own Peixing Zhang framed the sequel as a manufacturing problem: every added design element "is going to level up the biomanufacturing challenge," from squeezing larger cargo into a capsid to holding "comparable product quality, batch to batch... in a cost-effective manner." (Discovery Matters)

And someone is solving the cargo limit head-on. On RARECast, SpliceBio CEO Michael Villepelion explained the company's split-intein platform, it cuts a too-big gene in two, ships each half in its own AAV, and reconstitutes the full protein inside the cell, "independent on the cell type" and, he argues, "much more efficient than DNA and RNA approaches" to dual-AAV. The lead, SB007 for Stargardt (the large ABCA4 gene), is in a Phase 1 he says makes SpliceBio "the first to ever put inteins into humans," delivered subretinally into a population of "40,000 people in the US, roughly the same numbers in Europe" with no approved treatment. The prize he keeps pointing past the eye: dystrophin, the Duchenne gene that has defied AAV for the same reason. (RARECast)

The debate

The week's real fight is whether in-vivo is the destination or just the hype cycle's current stop. The bull case is on the tape and it's strong: in-vivo "really what that means... is simpler, faster, more accessible treatment for patients," no apheresis, no ex-vivo manufacturing, off-the-shelf, and strategics are paying up for it (Lilly/ORNA, plus the in-vivo CRISPR programs named above). (Cell & Gene)

The bear case was voiced in the same room and reinforced by the delivery experts. The roundtable's own editors conceded "not everybody is on board," and Discovery Matters spelled out why: targeting tissue beyond the liver with a "blind vehicle" is still being solved amino acid by amino acid, and each layer of cleverness makes the product harder and costlier to manufacture consistently. (Discovery Matters) The honest read: the capital has committed to in-vivo, but durability and tissue-targeting beyond liver/eye remain unproven, and no operator stood up this week to claim those problems are behind us.

Read-throughs & names in play

  • uniQure (QURE). Direct beneficiary, and the cleanest proxy for the FDA regime change. Bull: a disease-modifying CNS gene therapy with an accelerated path and the sham-control overhang lifted; Q3 filing is the near catalyst. Bear: tiny patient numbers and a thin data package underpin the accelerated nod, the confirmatory trial is where the thesis lives or dies. (The Readout Loud)
  • Eli Lilly (LLY), Intellia (NTLA), Regeneron (REGN). Named as the in-vivo standard-setters. Lilly's ORNA deal puts a circular-RNA, in-vivo CAR-T platform inside big pharma; NTLA and REGN anchor the in-vivo editing/gene-therapy validation case. The shared bear remains durability and delivery past the liver. (Cell & Gene)
  • Danaher (DHR) / Cytiva, and the viral-vector CDMO complex. The week's delivery enthusiasm is a picks-and-shovels read for vector manufacturing, every added capsid design element is more process to equip and validate, exactly Cytiva's franchise. The China angle (Westlake) is a reminder the demand base is global. (Discovery Matters)
  • Abeona (ABEO) / INmune Bio (INMB). On BioSpace, Abeona CEO Vish Sasadri detailed its FDA-approved autologous gene-corrected skin graft for RDEB, collagen-7-producing keratinocyte sheets, ~20-25 days to manufacture per patient, with durability data now "12 years after a one-time therapy." It's the live case study in commercial cell-therapy logistics: real approval, real benefit, real manufacturing and travel friction. (BioSpace)
  • Bioprocessing hosts (Sartorius, Repligen, Thermo's BioProduction). On Smart Biotech Scientist, David Brühlmann's verdict was that CHO "doesn't lose" for standard glycosylated mAbs, 5-10 g/L titers, hundreds of approvals, CDMO capacity everywhere, while moss, plant, silkworm and microalgae hosts each win only a niche. Translation for the consumables names: the CHO mAb core that anchors single-use demand isn't going anywhere. (Smart Biotech Scientist)

What changed

Two weeks ago the in-vivo CAR-T deal driving the conversation was a price tag without a name; this week the editors put the name on it, Eli Lilly's ORNA, a circular-RNA in-vivo CAR-T platform. And the Stargardt/ABCA4 target that surfaced last week via an RNA-editing pitch now has a second modality on the tape, SpliceBio's dual-AAV protein splicing, so the large-gene retina race is heating up, not consolidating. (Cell & Gene; RARECast) The bigger delta is regulatory mood: the FDA reads as constructive again, the same agency the roundtable says is now pushing a "real-time" trials initiative to kill the "45%" of timelines that is "dead time." (Cell & Gene)

What didn't show up

No anti-amyloid launch tape, again. Nothing on Leqembi patient starts, SubQ, ARIA or CMS coverage from Biogen/Eisai, and nothing on Lilly's Kisunla; the week's neuro story was a Huntington's gene therapy, not the amyloid franchises. No fresh company-specific data from CRISPR Therapeutics, Beam or Verve, and no podcast coverage of Illumina, Thermo Fisher, Danaher, Agilent, Revvity, Bruker or Waters in their own voice. Where there was no tape, we left the line blank rather than fill it.